TS-134 is under clinical development by Taisho Pharmaceutical and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TS-134’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TS-134 overview
TS-134 is under development for the treatment of schizophrenia. The drug candidate is administered orally as a solution and tablet form. The drug candidate targets metabotropic glutamate 2 and 3 receptors. The drug candidate is a lipophilic prodrug of MGS0008.
Taisho Pharmaceutical overview
Taisho Pharmaceutical develops, manufactures and markets self-medication drugs and prescription pharmaceuticals. The company’s self-medication products comprise over the counter (OTC) products, quasi-drugs and health food products. Its prescription pharmaceuticals portfolio includes ethical drugs in the fields of infectious diseases, orthopedic disorders, central nervous system (CNS) diseases and metabolic diseases. Taisho Pharmaceutical provide its products under Pabron, Lipovitan D, Riup, Livita, Colac, Zosyn, Clarith, Edirol, Palux, Geninax, and Lorcam brand names. The company operates through its subsidiaries located in the Philippines, Indonesia, Malaysia, Thailand, Vietnam, China, Singapore, Taiwan and the US. Taisho Pharmaceutical is headquartered in Toshima-ku, Tokyo, Japan.
For a complete picture of TS-134’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.